Bayer sues Watson to block copycat Beyaz; Sun Pharma posts big rise in profits, sales;

@FiercePharma: More fallout from Ben Venue's manufacturing snafu: Childhood leukemia drug may run out w/in 2 weeks--NYT. News | Follow @FiercePharma

> A Bayer ($BAY) unit is suing Watson Pharmaceuticals ($WPI) over the generics maker's bid to knock off the birth-control pill Beyaz. More

> India's Sun Pharmaceutical beat analyst estimates with a 91% increase in profits for its fiscal third quarter; sales grew by 37%. Report

> The FDA issued guidelines for safe production of the bloodthinner heparin, which was caught up in a contamination scandal four years ago. Story

> AmerisourceBergen CFO Michael DiCandilo is leaving "to pursue other interests," with controller Tim Guttman stepping in as interim CFO until a replacement is found. News

> Bristol-Myers Squibb ($BMY) wrapped up its $26-per-share tender offer for Inhibitex ($INHX) with about 91% of the outstanding stock. Article

> The Russian pharmaceutical market is expected to continue its "stupendous growth" through 2013, the market resesarch firm RNCOS said. Report

> The Obama administration's compromise on birth control puts insurers on the hook for covering the cost of their members' free contraception. Story

Biotech News

@FierceBiotech: Scientists at JHU have developed a virtual tool, Pyromaker, that can aid in analysis of complex genetic mutations. Release | Follow @FierceBiotech

@JohnCFierce: Last week's headlines on mouse study and bexarotene inspired some Alzheimer's patients to ask for an Rx. More | Follow @JohnCFierce

@RyanMFierce: A German drug data firm got slammed for potential privacy violations after selling Big Pharma groups raw script data. Story | Follow @RyanMFierce

@FierceMedDev: J&J could invest in Salt Lake City-based Coherex Medical (Update) (@deseretnews). News | Follow @FierceMedDev

> U.K. charities campaign to modify pricey regs in trials directive. Article

> Hungry Valeant snags Eyetech in ongoing buyout spree. News

IT News

> Belgian researchers access CLC bio's sequence analysis software. Story

> EMC to found Russian cloud computing, 'Big Data' hub. More

> Eagle Genomics, Cycle Computing win bid to develop bioinformatics solutions. News

> CRO ESTERN, Nextrials sign software agreement. Article

> German drug data outfit slammed for potential privacy breach. Item

Medical Device News

> What's next for Stryker after MacMillan's exit? Story

> Nodality, UCB Pharma ink multiyear companion diagnostics deal. Piece

> Is medical tech the answer for Sony? Item

> Court upholds $371M patent decision against W.L. Gore, favoring Bard. Story

> EU seeks greater oversight after breast implant hysteria. Report

> Rogers, Markey seek new life for unpopular pediatric device rule. Article

And Finally... GlaxoSmithKline ($GSK) is sifting traditional Chinese medicine for principles handy to contemporary R&D. More

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.